The Motley Fool
19 Nov 2026, 23:45 UTC · 59m ago
Johnson & Johnson Delivered 'Immaculate' Prostate Cancer Data at ESMO. Here's Why Investors Should Care
Impact · against what's priced in
The early-stage success of JNJ-6143 is positive but immaterial to JNJ's current valuation. Because the drug is only in Phase 1, it does not provide the immediate revenue acceleration needed to bridge the gap between current 6% growth and the 13.1% implied by the stock price.
- JNJ+0.05
Challenges what's priced in
- The price assumes
The $50 billion oncology sales target for 2030





